Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 653,289
- Total 13F value
- $1,241,249
- Share change
- -97,812,263
- SEC-reported price per share
- $1.90
- Number of holders
- 2
- Value change
- -$59,123,616
- Number of sells
- 90
- Shares outstanding
- 94,372,096
Holder snapshot
5 signals
Security identity
Who this page is about.
1 source field
Report period
Q2 2025
Institutions
2
Top holders
2
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
09 Jun 2025
13F
13D/G
3/4/5
Lead comparable stake: 4.8%
13D/G row: VANGUARD GROUP INC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 5
VANGUARD GROUP INC
4.8%
BlackRock, Inc.
3%
ORBIMED ADVISORS LLC
1.7%
Mark Baldry
0.03%
Natasha Fay Thoren
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
4.8%
from 13D/G
|
$1,903,935
8,067,516 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
13D/G
Company
|
3%
from 13D/G
|
$2,702,123
11,430,304 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
1.7%
from 13D/G
|
$1,601,968
6,776,515 shares
|
— | 31 Mar 2025 |
| Mark Baldry |
3/4/5
Chief Commercial Officer
|
0.03%
|
$62,886
25,337 shares
|
— | 16 May 2025 |
| Natasha Fay Thoren |
3/4/5
Chief Legal Officer
|
0.01%
|
$1,797
9,462 shares
|
— | 20 May 2025 |
| Keith Woods |
3/4/5
Director
|
0.01%
|
$1,140
6,000 shares
|
— | 09 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
653,289
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
91
Q2 2025 holders
2
Holder diff
-89
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend